Case report shows symptom relief after off-label mavacamten use in a patient with mid-ventricular obstruction, suggesting its potential role.
We present a 63-year-old man with mid-ventricular obstructive HCM and exertional dyspnoea despite maximal beta-blocker therapy. Initiation of Mavacamten, a myosin inhibitor, as an off-label treatment led to significant symptom relief and gradient reduction. This case highlights the potential role of Mavacamten in mid-ventricular obstruction, underscoring the need for further trials to evaluate its broader clinical application in this subset of HCM patients.
No takes yet. Share an insight, caveat, or question.
Hunziker et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: